Arbidol
ApprovedSmall molecule
Arbidol is one of 109 small molecule programs targeting Common Cold. It is currently in Approved.
4
Indications
6
Total Trials
1
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Arbidol
SShengjing Hospital
Approved
Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Influenza1 trial
Severe Influenza Trial of ARbidol
Completed·—·Phase 3·NCT03787459·200 enrolled
Common Cold1 trial
Pneumonia1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Arbidol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SShengjing Hospital